甲磺酸伊马替尼致红皮病一例  

Erythroderma induced by imatinib mesylate:a case report

作　　者：聂芳娜 段明辉[2] 张路[2] NIE Fangna;DUAN Minghui;ZHANG Lu(Department of Hematology and Oncology,The First Hospital of Fangshan District,Beijing 102400,China;Department of Hematology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China)

机构地区：[1]北京市房山区第一医院血液肿瘤科,北京102400 [2]中国医学科学院北京协和医学院北京协和医院血液内科,北京100730

出　　处：《临床药物治疗杂志》2024年第12期87-89,共3页Clinical Medication Journal

摘　　要：本文报道1例中年女性患者应用甲磺酸伊马替尼致红皮病的不良反应。患者确诊为慢性髓系白血病慢性期,给予甲磺酸伊马替尼治疗,用药2.5个月后,患者出现严重的皮肤病变,诊断为红皮病,予糖皮质激素等治疗,原发疾病方面换为氟马替尼治疗后皮疹消退,随访白血病控制良好。在甲磺酸伊马替尼治疗慢性髓系白血病的过程中,应警惕红皮病的发生风险。This article reports an adverse event of a middle-aged female patient with erythroderma induced by imatinib mesylate.The patient was diagnosed with chronic myeloid leukemia in the chronic phase(CML-CP)and was treated with imatinib mesylate.After 2.5 months of treatment,the patient developed severe skin lesions and was diagnosed with erythroderma.She was then treated with glucocorticoids,and imatinib mesylate was replaced by flumatinib for the primary disease.Subsequently,the rash subsided,and the leukemia has been well-controlled so far during follow-up.In the treatment of chronic myeloid leukemia with imatinib mesylate,the risk of erythroderma should be vigilantly monitored.

关 键 词：伊马替尼 红皮病 泼尼松 

分 类 号：R973[医药卫生—药品] R969.3[医药卫生—药学]